It is important to note that in this situation there is a high rate of tumour multifocality and lymph-node metastases, including a relatively high rate of "skip" metastases
individual tolerance should guide choices
The trial evaluated once-weekly subcutaneous semaglutide 2.4 mg versus placebo in reducing the risk of MACE (a composite endpoint comprising CV death, nonfatal MI or nonfatal stroke) in individuals with established ASCVD and overweight or obesity but without diabetes
World patent WO2010059771 (2010)
Episodes of intense flushing and persistent redness are common, and in some cases, individuals may develop rhinophyma, a thickening of the skin on the nose that can be particularly distressing
Side Effects in Men Side effects of semaglutide are generally similar in men and women, with a few male-specific considerations